ENSG00000127616 |
|
colorectal adenocarcinoma |
frameshift_variant |
7.39% (92/1245) |
2 entries |
ENSG00000127616 |
|
Ovarian Small Cell Carcinoma |
frameshift_variant |
64.06% (41/64) |
5 entries |
ENSG00000127616 |
|
colon adenocarcinoma |
missense_variant |
6.959% (92/1322) |
10 entries |
ENSG00000127616 |
|
colorectal adenocarcinoma |
missense_variant |
7.39% (92/1245) |
4 entries |
ENSG00000127616 |
|
Ovarian Small Cell Carcinoma |
sequence_alteration |
64.06% (41/64) |
4 entries |
ENSG00000127616 |
|
colon adenocarcinoma |
frameshift_variant |
6.959% (92/1322) |
5 entries |
ENSG00000127616 |
|
Ovarian Small Cell Carcinoma |
stop_gained |
64.06% (41/64) |
4 entries |
ENSG00000127616 |
|
colorectal adenocarcinoma |
sequence_alteration |
7.39% (92/1245) |
1 entry |
ENSG00000127616 |
|
colon adenocarcinoma |
sequence_alteration |
6.959% (92/1322) |
6 entries |
ENSG00000127616 |
|
esophageal adenocarcinoma |
missense_variant |
7.117% (39/548) |
3 entries |
ENSG00000127616 |
|
esophageal adenocarcinoma |
sequence_alteration |
7.117% (39/548) |
1 entry |
ENSG00000127616 |
|
Ovarian Small Cell Carcinoma |
conservative_inframe_deletion |
64.06% (41/64) |
1 entry |
ENSG00000127616 |
|
esophageal adenocarcinoma |
stop_gained |
7.117% (39/548) |
2 entries |
ENSG00000127616 |
|
lung adenocarcinoma |
sequence_alteration |
8.225% (216/2626) |
6 entries |
ENSG00000127616 |
|
lung adenocarcinoma |
stop_gained |
8.225% (216/2626) |
10 entries |
ENSG00000127616 |
|
lung adenocarcinoma |
missense_variant |
8.225% (216/2626) |
10 entries |
ENSG00000127616 |
|
lung adenocarcinoma |
frameshift_variant |
8.225% (216/2626) |
4 entries |
ENSG00000127616 |
|
colon adenocarcinoma |
stop_gained |
6.959% (92/1322) |
4 entries |
ENSG00000127616 |
|
pulmonary blastoma |
missense_variant |
6.25% (2/32) |
1 entry |
ENSG00000127616 |
|
Endometrial Clear Cell Adenocarcinoma |
missense_variant |
11.11% (3/27) |
2 entries |
ENSG00000127616 |
|
lung adenocarcinoma |
amino_acid_insertion |
8.225% (216/2626) |
1 entry |
ENSG00000127616 |
|
Malignant Mesothelioma |
missense_variant |
28.57% (2/7) |
1 entry |
ENSG00000127616 |
|
kidney Wilms tumor |
missense_variant |
0.8357% (3/359) |
1 entry |
ENSG00000127616 |
|
esophageal squamous cell carcinoma |
missense_variant |
1.458% (10/686) |
5 entries |
ENSG00000127616 |
|
prostate adenocarcinoma |
missense_variant |
2.061% (45/2183) |
2 entries |
ENSG00000127616 |
|
cecum adenocarcinoma |
frameshift_variant |
5.797% (16/276) |
1 entry |
ENSG00000127616 |
|
non-small cell lung carcinoma |
missense_variant |
5.634% (12/213) |
3 entries |
ENSG00000127616 |
|
Sarcomatoid Mesothelioma |
missense_variant |
100.0% (2/2) |
1 entry |
ENSG00000127616 |
|
non-small cell lung carcinoma |
stop_gained |
5.634% (12/213) |
2 entries |
ENSG00000127616 |
|
lobular breast carcinoma |
sequence_alteration |
1.544% (4/259) |
1 entry |
ENSG00000127616 |
|
bladder carcinoma |
missense_variant |
4.448% (25/562) |
1 entry |
ENSG00000127616 |
|
Mantle cell lymphoma |
missense_variant |
8.738% (9/103) |
2 entries |
ENSG00000127616 |
|
nasopharyngeal squamous cell carcinoma |
missense_variant |
0.974% (3/308) |
2 entries |
ENSG00000127616 |
|
non-small cell lung carcinoma |
sequence_alteration |
5.634% (12/213) |
1 entry |
ENSG00000127616 |
|
cecum adenocarcinoma |
sequence_alteration |
5.797% (16/276) |
1 entry |
ENSG00000127616 |
|
Gallbladder Adenocarcinoma |
missense_variant |
4.848% (8/165) |
2 entries |
ENSG00000127616 |
|
lung carcinoma |
sequence_alteration |
6.818% (12/176) |
1 entry |
ENSG00000127616 |
|
Burkitts lymphoma |
missense_variant |
7.018% (4/57) |
1 entry |
ENSG00000127616 |
|
Pleural Epithelioid Mesothelioma |
missense_variant |
1.0% (2/200) |
1 entry |
ENSG00000127616 |
|
Meningeal Melanocytoma |
missense_variant |
10.53% (2/19) |
1 entry |
ENSG00000127616 |
|
hepatocellular carcinoma |
missense_variant |
2.677% (28/1046) |
3 entries |
ENSG00000127616 |
|
cervical squamous cell carcinoma |
missense_variant |
2.462% (8/325) |
1 entry |
ENSG00000127616 |
|
basal cell carcinoma |
missense_variant |
8.824% (6/68) |
2 entries |
ENSG00000127616 |
|
gastric adenocarcinoma |
sequence_alteration |
3.742% (36/962) |
1 entry |
ENSG00000127616 |
|
clear cell renal carcinoma |
sequence_alteration |
1.711% (28/1636) |
1 entry |
ENSG00000127616 |
|
skin melanoma |
sequence_alteration |
5.214% (62/1189) |
2 entries |
ENSG00000127616 |
|
large cell medulloblastoma |
missense_variant |
7.692% (2/26) |
1 entry |
ENSG00000127616 |
|
anaplastic astrocytoma |
missense_variant |
5.303% (7/132) |
1 entry |
ENSG00000127616 |
|
papillary thyroid carcinoma |
missense_variant |
0.5871% (3/511) |
2 entries |
ENSG00000127616 |
|
chronic lymphocytic leukemia |
sequence_alteration |
0.5612% (5/891) |
1 entry |
ENSG00000127616 |
|
bile duct adenocarcinoma |
frameshift_variant |
2.387% (10/419) |
3 entries |
ENSG00000127616 |
|
esophageal adenocarcinoma |
conservative_inframe_deletion |
7.117% (39/548) |
1 entry |
ENSG00000127616 |
|
oral squamous cell carcinoma |
missense_variant |
1.894% (5/264) |
2 entries |
ENSG00000127616 |
|
squamous cell lung carcinoma |
frameshift_variant |
2.664% (26/976) |
1 entry |
ENSG00000127616 |
|
T-cell acute lymphoblastic leukemia |
missense_variant |
1.681% (10/595) |
2 entries |
ENSG00000127616 |
|
breast ductal adenocarcinoma |
sequence_alteration |
4.19% (67/1599) |
1 entry |
ENSG00000127616 |
|
pancreatic carcinoma |
sequence_alteration |
1.136% (2/176) |
1 entry |
ENSG00000127616 |
|
breast ductal adenocarcinoma |
missense_variant |
4.19% (67/1599) |
2 entries |
ENSG00000127616 |
|
melanoma |
missense_variant |
5.031% (8/159) |
4 entries |
ENSG00000127616 |
|
renal carcinoma |
missense_variant |
10.0% (2/20) |
1 entry |
ENSG00000127616 |
|
clear cell renal carcinoma |
missense_variant |
1.711% (28/1636) |
9 entries |
ENSG00000127616 |
|
gastric adenocarcinoma |
frameshift_variant |
3.742% (36/962) |
2 entries |
ENSG00000127616 |
|
anaplastic oligodendroglioma |
missense_variant |
7.692% (7/91) |
1 entry |
ENSG00000127616 |
|
ovarian serous adenocarcinoma |
missense_variant |
0.7946% (7/881) |
3 entries |
ENSG00000127616 |
|
Extramammary Paget Disease |
stop_gained |
66.67% (2/3) |
2 entries |
ENSG00000127616 |
|
Ovarian Small Cell Carcinoma |
missense_variant |
64.06% (41/64) |
1 entry |
ENSG00000127616 |
|
ovarian clear cell adenocarcinoma |
missense_variant |
9.615% (5/52) |
4 entries |
ENSG00000127616 |
|
prostate carcinoma |
sequence_alteration |
3.991% (17/426) |
1 entry |
ENSG00000127616 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
missense_variant |
2.273% (6/264) |
2 entries |
ENSG00000127616 |
|
Dysplasia in Ulcerative Colitis |
missense_variant |
25.0% (2/8) |
1 entry |
ENSG00000127616 |
|
breast ductal adenocarcinoma |
stop_gained |
4.19% (67/1599) |
2 entries |
ENSG00000127616 |
|
Endometrial Endometrioid Adenocarcinoma |
missense_variant |
4.938% (32/648) |
1 entry |
ENSG00000127616 |
|
prostate adenocarcinoma |
sequence_alteration |
2.061% (45/2183) |
1 entry |
ENSG00000127616 |
|
urothelial carcinoma |
missense_variant |
13.95% (12/86) |
1 entry |
ENSG00000127616 |
|
non-small cell lung carcinoma |
frameshift_variant |
5.634% (12/213) |
2 entries |
ENSG00000127616 |
|
Adrenal Gland Neuroblastoma |
missense_variant |
3.333% (2/60) |
1 entry |
ENSG00000127616 |
|
clear cell renal carcinoma |
frameshift_variant |
1.711% (28/1636) |
1 entry |
ENSG00000127616 |
|
Merkel cell skin cancer |
missense_variant |
12.63% (12/95) |
3 entries |
ENSG00000127616 |
|
diffuse gastric adenocarcinoma |
missense_variant |
4.878% (4/82) |
2 entries |
ENSG00000127616 |
|
rectal adenocarcinoma |
missense_variant |
3.114% (17/546) |
4 entries |
ENSG00000127616 |
|
ovarian teratoma |
missense_variant |
7.143% (4/56) |
1 entry |
ENSG00000127616 |
|
T-cell acute lymphoblastic leukemia |
sequence_alteration |
1.681% (10/595) |
1 entry |
ENSG00000127616 |
|
acute myeloid leukemia |
sequence_alteration |
0.5507% (5/908) |
1 entry |
ENSG00000127616 |
|
squamous cell lung carcinoma |
stop_gained |
2.664% (26/976) |
2 entries |
ENSG00000127616 |
|
cecum adenocarcinoma |
missense_variant |
5.797% (16/276) |
2 entries |
ENSG00000127616 |
|
ovarian carcinoma |
frameshift_variant |
17.39% (4/23) |
1 entry |
ENSG00000127616 |
|
gastric adenocarcinoma |
missense_variant |
3.742% (36/962) |
3 entries |
ENSG00000127616 |
|
hepatocellular carcinoma |
sequence_alteration |
2.677% (28/1046) |
1 entry |
ENSG00000127616 |
|
metaplastic breast carcinoma |
missense_variant |
3.333% (2/60) |
2 entries |
ENSG00000127616 |
|
breast carcinoma |
stop_gained |
1.176% (18/1531) |
1 entry |
ENSG00000127616 |
|
female breast carcinoma |
missense_variant |
2.527% (7/277) |
2 entries |
ENSG00000127616 |
|
bile duct adenocarcinoma |
missense_variant |
2.387% (10/419) |
3 entries |
ENSG00000127616 |
|
colorectal adenocarcinoma |
conservative_inframe_deletion |
7.39% (92/1245) |
1 entry |
ENSG00000127616 |
|
urothelial carcinoma |
frameshift_variant |
13.95% (12/86) |
1 entry |
ENSG00000127616 |
|
Merkel cell skin cancer |
sequence_alteration |
12.63% (12/95) |
1 entry |
ENSG00000127616 |
|
squamous cell lung carcinoma |
missense_variant |
2.664% (26/976) |
4 entries |
ENSG00000127616 |
|
breast carcinoma |
missense_variant |
1.176% (18/1531) |
3 entries |
ENSG00000127616 |
|
diffuse large B-cell lymphoma |
missense_variant |
1.617% (6/371) |
3 entries |
ENSG00000127616 |
|
chronic lymphocytic leukemia |
missense_variant |
0.5612% (5/891) |
1 entry |
ENSG00000127616 |
|
gastric intestinal type adenocarcinoma |
missense_variant |
8.235% (7/85) |
1 entry |
ENSG00000127616 |
|
Endometrial Endometrioid Adenocarcinoma |
conservative_inframe_deletion |
4.938% (32/648) |
1 entry |
ENSG00000127616 |
|
central nervous system primitive neuroectodermal neoplasm |
missense_variant |
3.233% (15/464) |
5 entries |
ENSG00000127616 |
|
esophageal squamous cell carcinoma |
stop_gained |
1.458% (10/686) |
2 entries |
ENSG00000127616 |
|
glioma |
missense_variant |
1.645% (10/608) |
2 entries |
ENSG00000127616 |
|
medullary thyroid gland carcinoma |
missense_variant |
4.054% (3/74) |
2 entries |
ENSG00000127616 |
|
adenosquamous lung carcinoma |
stop_gained |
13.04% (3/23) |
1 entry |
ENSG00000127616 |
|
T-cell acute lymphoblastic leukemia |
amino_acid_insertion |
1.681% (10/595) |
2 entries |
ENSG00000127616 |
|
skin melanoma |
missense_variant |
5.214% (62/1189) |
8 entries |
ENSG00000127616 |
|
osteosarcoma |
missense_variant |
1.299% (2/154) |
2 entries |
ENSG00000127616 |
|
Gallbladder Adenocarcinoma |
sequence_alteration |
4.848% (8/165) |
1 entry |
ENSG00000127616 |
|
small cell lung carcinoma |
stop_gained |
3.905% (18/461) |
1 entry |
ENSG00000127616 |
|
urothelial carcinoma |
stop_gained |
13.95% (12/86) |
1 entry |
ENSG00000127616 |
|
medulloblastoma |
missense_variant |
20.83% (5/24) |
1 entry |
ENSG00000127616 |
|
colon adenocarcinoma |
conservative_inframe_deletion |
6.959% (92/1322) |
1 entry |
ENSG00000127616 |
|
pancreatic ductal adenocarcinoma |
missense_variant |
3.541% (67/1892) |
5 entries |
ENSG00000127616 |
|
pancreatic ductal adenocarcinoma |
frameshift_variant |
3.541% (67/1892) |
2 entries |
ENSG00000127616 |
|
lobular breast carcinoma |
missense_variant |
1.544% (4/259) |
1 entry |
ENSG00000127616 |
|
brain glioblastoma |
missense_variant |
1.071% (13/1214) |
5 entries |
ENSG00000127616 |
|
small cell lung carcinoma |
missense_variant |
3.905% (18/461) |
4 entries |
ENSG00000127616 |
|
gastric adenocarcinoma |
stop_gained |
3.742% (36/962) |
3 entries |
ENSG00000127616 |
|
melanoma |
sequence_alteration |
5.031% (8/159) |
1 entry |
ENSG00000127616 |
|
bladder transitional cell carcinoma |
missense_variant |
6.71% (31/462) |
3 entries |
ENSG00000127616 |
|
ovarian clear cell adenocarcinoma |
frameshift_variant |
9.615% (5/52) |
1 entry |
ENSG00000127616 |
|
clear cell renal carcinoma |
conservative_inframe_deletion |
1.711% (28/1636) |
1 entry |
ENSG00000127616 |
|
Invasive Breast Carcinoma |
missense_variant |
2.174% (1/46) |
1 entry |
ENSG00000127616 |
|
diffuse gastric adenocarcinoma |
sequence_alteration |
4.878% (4/82) |
1 entry |
ENSG00000127616 |
|
nasopharyngeal squamous cell carcinoma |
frameshift_variant |
0.974% (3/308) |
1 entry |
ENSG00000127616 |
|
Duodenal Adenocarcinoma |
missense_variant |
5.882% (1/17) |
1 entry |
ENSG00000127616 |
|
chromophobe renal cell carcinoma |
missense_variant |
0.6757% (1/148) |
1 entry |
ENSG00000127616 |
|
Appendix Adenocarcinoma |
sequence_alteration |
1.351% (1/74) |
1 entry |
ENSG00000127616 |
|
pancreatic ductal adenocarcinoma |
conservative_inframe_deletion |
3.541% (67/1892) |
1 entry |
ENSG00000127616 |
|
Pancreatic Acinar Cell Carcinoma |
missense_variant |
2.941% (1/34) |
1 entry |
ENSG00000127616 |
|
hemangioblastoma |
sequence_alteration |
8.571% (3/35) |
1 entry |
ENSG00000127616 |
|
atypical teratoid rhabdoid tumor |
stop_gained |
4.167% (1/24) |
1 entry |
ENSG00000127616 |
|
lung neoplasm |
frameshift_variant |
100.0% (1/1) |
1 entry |
ENSG00000127616 |
|
neoplasm of mature B-cells |
missense_variant |
1.639% (1/61) |
1 entry |
ENSG00000127616 |
|
ovarian serous adenocarcinoma |
sequence_alteration |
0.7946% (7/881) |
1 entry |
ENSG00000127616 |
|
mucosal melanoma |
missense_variant |
1.429% (1/70) |
1 entry |
ENSG00000127616 |
|
gastric intestinal type adenocarcinoma |
frameshift_variant |
8.235% (7/85) |
1 entry |
ENSG00000127616 |
|
melanoma |
frameshift_variant |
5.031% (8/159) |
1 entry |
ENSG00000127616 |
|
nasopharyngeal squamous cell carcinoma |
stop_gained |
0.974% (3/308) |
1 entry |
ENSG00000127616 |
|
embryonal rhabdomyosarcoma |
conservative_inframe_deletion |
2.247% (2/89) |
1 entry |
ENSG00000127616 |
|
Lung Sarcomatoid Carcinoma |
sequence_alteration |
7.143% (1/14) |
1 entry |
ENSG00000127616 |
|
hepatocellular carcinoma |
frameshift_variant |
2.677% (28/1046) |
1 entry |
ENSG00000127616 |
|
pseudomyxoma peritonei |
missense_variant |
10.0% (1/10) |
1 entry |
ENSG00000127616 |
|
cervical carcinoma |
missense_variant |
8.696% (2/23) |
1 entry |
ENSG00000127616 |
|
ovarian carcinoma |
stop_gained |
17.39% (4/23) |
1 entry |
ENSG00000127616 |
|
melanoma |
stop_gained |
5.031% (8/159) |
1 entry |
ENSG00000127616 |
|
lobular breast carcinoma |
frameshift_variant |
1.544% (4/259) |
1 entry |
ENSG00000127616 |
|
skin melanoma |
frameshift_variant |
5.214% (62/1189) |
1 entry |
ENSG00000127616 |
|
breast ductal adenocarcinoma |
conservative_inframe_deletion |
4.19% (67/1599) |
1 entry |
ENSG00000127616 |
|
rectal adenocarcinoma |
frameshift_variant |
3.114% (17/546) |
1 entry |
ENSG00000127616 |
|
head and neck squamous cell carcinoma |
missense_variant |
0.1277% (1/783) |
1 entry |
ENSG00000127616 |
|
Ampulla of Vater Carcinoma |
conservative_inframe_deletion |
1.176% (1/85) |
1 entry |
ENSG00000127616 |
|
prostate carcinoma |
stop_gained |
3.991% (17/426) |
1 entry |
ENSG00000127616 |
|
anaplastic oligoastrocytoma |
missense_variant |
1.852% (1/54) |
1 entry |
ENSG00000127616 |
|
gastric adenocarcinoma |
conservative_inframe_deletion |
3.742% (36/962) |
1 entry |
ENSG00000127616 |
|
prostate carcinoma |
missense_variant |
3.991% (17/426) |
1 entry |
ENSG00000127616 |
|
Gallbladder Adenocarcinoma |
stop_gained |
4.848% (8/165) |
1 entry |
ENSG00000127616 |
|
Benign Adrenal Gland Pheochromocytoma |
missense_variant |
3.03% (1/33) |
1 entry |
ENSG00000127616 |
|
Cortisol-Producing Adrenal Cortex Adenoma |
conservative_inframe_deletion |
0.8065% (1/124) |
1 entry |
ENSG00000127616 |
|
HER2 Positive Breast Carcinoma |
missense_variant |
4.348% (6/138) |
1 entry |
ENSG00000127616 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
frameshift_variant |
2.273% (6/264) |
1 entry |
ENSG00000127616 |
|
Testicular Yolk Sac Tumor |
missense_variant |
14.29% (1/7) |
1 entry |
ENSG00000127616 |
|
hemangioblastoma |
conservative_inframe_deletion |
8.571% (3/35) |
1 entry |
ENSG00000127616 |
|
salivary gland carcinoma |
stop_gained |
3.03% (1/33) |
1 entry |
ENSG00000127616 |
|
Mantle cell lymphoma |
stop_gained |
8.738% (9/103) |
1 entry |
ENSG00000127616 |
|
anaplastic astrocytoma |
conservative_inframe_deletion |
5.303% (7/132) |
1 entry |
ENSG00000127616 |
|
large cell lung carcinoma |
frameshift_variant |
6.667% (2/30) |
1 entry |
ENSG00000127616 |
|
hemangioblastoma |
missense_variant |
8.571% (3/35) |
1 entry |
ENSG00000127616 |
|
lung carcinoma |
frameshift_variant |
6.818% (12/176) |
1 entry |
ENSG00000127616 |
|
papillary renal cell carcinoma |
conservative_inframe_deletion |
2.062% (8/388) |
1 entry |
ENSG00000127616 |
|
breast ductal adenocarcinoma |
frameshift_variant |
4.19% (67/1599) |
1 entry |
ENSG00000127616 |
|
Salivary Gland Small Cell Carcinoma |
missense_variant |
100.0% (1/1) |
1 entry |
ENSG00000127616 |
|
multiple myeloma |
missense_variant |
2.222% (1/45) |
1 entry |
ENSG00000127616 |
|
renal cell carcinoma |
missense_variant |
1.449% (1/69) |
1 entry |
ENSG00000127616 |
|
colon carcinoma |
frameshift_variant |
12.5% (1/8) |
1 entry |
ENSG00000127616 |
|
well-differentiated liposarcoma |
missense_variant |
5.556% (1/18) |
1 entry |
ENSG00000127616 |
|
bladder transitional cell carcinoma |
sequence_alteration |
6.71% (31/462) |
1 entry |
ENSG00000127616 |
|
central nervous system primitive neuroectodermal neoplasm |
stop_gained |
3.233% (15/464) |
1 entry |
ENSG00000127616 |
|
T-cell acute lymphoblastic leukemia |
frameshift_variant |
1.681% (10/595) |
1 entry |
ENSG00000127616 |
|
medullary thyroid gland carcinoma |
stop_gained |
4.054% (3/74) |
1 entry |
ENSG00000127616 |
|
ependymoma |
missense_variant |
1.818% (1/55) |
1 entry |
ENSG00000127616 |
|
rectal adenocarcinoma |
conservative_inframe_deletion |
3.114% (17/546) |
1 entry |
ENSG00000127616 |
|
kidney Wilms tumor |
sequence_alteration |
0.8357% (3/359) |
1 entry |
ENSG00000127616 |
|
small cell carcinoma |
missense_variant |
33.33% (1/3) |
1 entry |
ENSG00000127616 |
|
colon carcinoma |
missense_variant |
12.5% (1/8) |
1 entry |
ENSG00000127616 |
|
brain astrocytoma |
missense_variant |
4.167% (2/48) |
1 entry |
ENSG00000127616 |
|
desmoplastic medulloblastoma |
missense_variant |
7.143% (1/14) |
1 entry |
ENSG00000127616 |
|
oral squamous cell carcinoma |
sequence_alteration |
1.894% (5/264) |
1 entry |
ENSG00000127616 |
|
breast phyllodes tumor |
missense_variant |
1.695% (1/59) |
1 entry |
ENSG00000127616 |
|
hemangioblastoma |
frameshift_variant |
8.571% (3/35) |
1 entry |
ENSG00000127616 |
|
Uveal Melanoma |
amino_acid_insertion |
0.7407% (1/135) |
1 entry |
ENSG00000127616 |
|
Tonsillar Squamous Cell Carcinoma |
missense_variant |
11.11% (1/9) |
1 entry |
ENSG00000127616 |
|
undifferentiated pleomorphic sarcoma |
missense_variant |
1.613% (1/62) |
1 entry |
ENSG00000127616 |
|
diffuse large B-cell lymphoma |
conservative_inframe_deletion |
1.617% (6/371) |
1 entry |
ENSG00000127616 |
|
Thymic Carcinoma |
missense_variant |
13.33% (2/15) |
1 entry |
ENSG00000127616 |
|
Intestinal Type Adenocarcinoma |
frameshift_variant |
100.0% (1/1) |
1 entry |
ENSG00000127616 |
|
ovarian carcinoma |
missense_variant |
17.39% (4/23) |
1 entry |
ENSG00000127616 |
|
adenosquamous lung carcinoma |
sequence_alteration |
13.04% (3/23) |
1 entry |
ENSG00000127616 |
|
sebaceous adenocarcinoma |
stop_gained |
33.33% (1/3) |
1 entry |
ENSG00000127616 |
|
bronchoalveolar adenocarcinoma |
missense_variant |
4.545% (1/22) |
1 entry |
ENSG00000127616 |
|
salivary gland squamous cell carcinoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000127616 |
|
nasal cavity and paranasal sinus carcinoma |
missense_variant |
4.348% (1/23) |
1 entry |
ENSG00000127616 |
|
Undifferentiated Ovarian Carcinoma |
frameshift_variant |
14.29% (1/7) |
1 entry |
ENSG00000127616 |
|
cecum adenocarcinoma |
stop_gained |
5.797% (16/276) |
1 entry |
ENSG00000127616 |
|
endometrium adenocarcinoma |
missense_variant |
3.333% (1/30) |
1 entry |
ENSG00000127616 |
|
small cell lung carcinoma |
frameshift_variant |
3.905% (18/461) |
1 entry |
ENSG00000127616 |
|
desmoplastic small round cell tumor |
missense_variant |
4.348% (1/23) |
1 entry |
ENSG00000127616 |
|
Thymic Carcinoma |
sequence_alteration |
13.33% (2/15) |
1 entry |
ENSG00000127616 |
|
large cell lung carcinoma |
stop_gained |
6.667% (2/30) |
1 entry |
ENSG00000127616 |
|
brain astrocytoma |
sequence_alteration |
4.167% (2/48) |
1 entry |
ENSG00000127616 |
|
Endometrial Undifferentiated Carcinoma |
missense_variant |
33.33% (1/3) |
1 entry |
ENSG00000127616 |
|
Pleural Mesothelioma |
missense_variant |
0.6944% (1/144) |
1 entry |
ENSG00000127616 |
|
Adamantinomatous Craniopharyngioma |
missense_variant |
7.692% (1/13) |
1 entry |
ENSG00000127616 |
|
bile duct adenocarcinoma |
stop_gained |
2.387% (10/419) |
1 entry |
ENSG00000127616 |
|
pancreatic ductal adenocarcinoma |
stop_gained |
3.541% (67/1892) |
1 entry |
ENSG00000127616 |
|
Breast Carcinoma by Gene Expression Profile |
sequence_alteration |
0.9901% (1/101) |
1 entry |
ENSG00000127616 |
|
ovarian serous adenocarcinoma |
frameshift_variant |
0.7946% (7/881) |
1 entry |
ENSG00000127616 |
|
hepatocellular carcinoma |
stop_gained |
2.677% (28/1046) |
1 entry |
ENSG00000127616 |
|
adrenal cortex carcinoma |
missense_variant |
0.5291% (1/189) |
1 entry |
ENSG00000127616 |
|
Unclassified Renal Cell Carcinoma |
missense_variant |
2.222% (1/45) |
1 entry |
ENSG00000127616 |
|
embryonal rhabdomyosarcoma |
missense_variant |
2.247% (2/89) |
1 entry |
ENSG00000127616 |
|
carcinosarcoma |
missense_variant |
33.33% (1/3) |
1 entry |
ENSG00000127616 |
|
cervical carcinoma |
sequence_alteration |
8.696% (2/23) |
1 entry |